Last reviewed · How we verify
NCT03686332: PERICLES
PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study
Phase 2 trial testing Arm A: Atezolizumab and Radiotherapy in Penile Cancer in 32 participants. Completed in 15 September 2023.
28 September 2022
Quick facts
| Lead sponsor | The Netherlands Cancer Institute |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 25 September 2018 |
| Primary completion | 28 September 2022 |
| Estimated completion | 15 September 2023 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Arm A: Atezolizumab and Radiotherapy — full drug profile →
- Arm B: Atezolizumab — full drug profile →
Conditions studied
- Penile Cancer — all drugs for Penile Cancer →
Sponsor
The Netherlands Cancer Institute
Who can join
18 and older, male only, with Penile Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with advanced penile cancer have a poor prognosis (21% 2-year overall survival from moment of diagnosis) and high morbidity due to progressive locoregional disease. Translational studies show high rates of infiltrating immune cells and PD-L1 positivity, suggesting that immunotherapy may be beneficial in this disease. Atezolizumab, targeting PD-L1, is active in several cancer types and is generally well-tolerated. This study will investigate whether atezolizumab can be combined with radiotherapy to control locoregional lymph node disease. Furthermore, the activity of atezolizumab in advanced penile cancer patients will be investigated.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
A global approach to improving penile cancer care.
Bandini M, Ahmed M, Basile G, Watkin N, et al · · 2022 · cited 45× · PMID 34937881 · DOI 10.1038/s41585-021-00557-y -
Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial.
Hahn AW, Chahoud J, Campbell MT, Karp DD, et al · · 2021 · cited 45× · PMID 33770291 · DOI 10.1007/s10637-021-01100-x -
An update on treatment of penile cancer.
Chadha J, Chahoud J, Spiess PE. · · 2022 · cited 35× · PMID 36172172 · DOI 10.1177/17588359221127254 -
Recent Advances in the Management of Penile Cancer: A Contemporary Review of the Literature.
Stecca CE, Alt M, Jiang DM, Chung P, et al · · 2021 · cited 31× · PMID 33454930 · DOI 10.1007/s40487-020-00135-z -
The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies.
Yu P, Zhu C, You X, Gu W, et al · · 2024 · cited 28× · PMID 38898003 · DOI 10.1038/s41419-024-06837-w -
The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy.
Ahmed ME, Falasiri S, Hajiran A, Chahoud J, et al · · 2020 · cited 28× · PMID 33080912 · DOI 10.3390/jcm9103334 -
Immune landscape and immunotherapy for penile cancer.
Tang Y, Hu X, Wu K, Li X. · · 2022 · cited 23× · PMID 36524123 · DOI 10.3389/fimmu.2022.1055235 -
Penile cancer: Updates in systemic therapy.
Joshi VB, Chadha J, Chahoud J. · · 2022 · cited 17× · PMID 36381603 · DOI 10.1016/j.ajur.2022.03.006
Verify or expand the search:
- PubMed search for NCT03686332
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Penile Cancer
Currently open trials in the same condition.
- NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
- NCT07054307 — MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinom · Phase 1 · recruiting
- NCT05639972 — E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers · Phase 1, PHASE2 · recruiting
- NCT06684327 — Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanc · Phase 2 · recruiting
- NCT06683846 — Ivonescimab in the Treatment of Multiple Advanced Tumors · Phase 2 · recruiting
Other The Netherlands Cancer Institute trials
Trials by the same sponsor.
- NCT07436858 — Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER · Phase 1 · not yet recruiting
- NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas · NA · recruiting
- NCT06931769 — TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer · recruiting
- NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
- NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03686332 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Netherlands Cancer Institute
- Last refreshed: 21 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03686332.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing